On September 19, NanoVation Therapeutics (NanoVation Corporation, headquartered in Canada) announced a multi-year R&D partnership with Novo Nordisk, To jointly advance the development of innovative genetic medicine for cardiac metabolic diseases and rare diseases.
The collaboration combines NanoVation's proprietary long-circulating lipid nanoparticle (lcLNP) RNA delivery technology with Novo Nordisk's expertise in cardiac metabolic and rare disease development and clinical translation.
Under the terms of the agreement, Novo Nordisk and NanoVation will collaborate on two major projects using base editing technology to treat certain rare genetic diseases, with future expansion to up to five additional targets for cardiac metabolic and rare diseases. Novo Nordisk will receive an exclusive worldwide license to NanoVation's LNP technology for these two major projects. NanoVation will receive research funding and be eligible for up to approximately $600 million in upfront payments and potential milestone payments.
Genetic medicine is at a critical juncture, and this collaboration marks an important milestone for NanoVation as an innovator in nucleic acid delivery by combining NanoVation's expertise in delivery outside the liver with Novo Nordisk's expertise in cardiometabolic and rare diseases. They have the potential to create truly transformative treatments.